SCHEMBL24327663

SCHEMBL24327663

COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1nc(Nc2cccc3c2N(S(C)(=O)=O)CC3)c2ncn(C)c2n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 16/20 0.59
▸ INSR P06213 13/20 0.59
▸ IGF1R P08069 13/20 0.59
▸ EGFR P00533 7/20 0.58
▸ MET P08581 3/20 0.55
▸ STK10 O94804 3/20 0.54
▸ ABL1 P00519 3/20 0.54
▸ LCK P06239 3/20 0.54
▸ FYN P06241 3/20 0.54
▸ FES P07332 3/20 0.54
▸ YES1 P07947 3/20 0.54
▸ HCK P08631 3/20 0.54
▸ ROS1 P08922 3/20 0.54
▸ FER P16591 3/20 0.54
▸ LTK P29376 3/20 0.54
▸ FLT3 P36888 3/20 0.54
▸ FRK P42685 3/20 0.54
▸ PTK2 Q05397 3/20 0.54
▸ BTK Q06187 3/20 0.54
▸ CAMK2G Q13555 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24327563 0.90 ALK (0.58) ALKINSRIGF1REGFRMET
SCHEMBL24327559 0.88 ALK (0.60) ALKINSRIGF1REGFRMET
SCHEMBL26778373 0.88 ALK (0.69) ALKINSRIGF1REGFRMET
SCHEMBL26778364 0.88 ALK (0.77) ALKINSRIGF1REGFRMET
SCHEMBL24327558 0.87 ALK (0.56) ALKINSRIGF1REGFRMET
SCHEMBL29661359 0.87 ALK (0.65) ALKINSRIGF1REGFRMET
SCHEMBL26655418 0.87 ALK (0.65) ALKINSRIGF1REGFRMET
SCHEMBL24327359 0.87 ALK (0.69) ALKINSRIGF1REGFRMET
SCHEMBL24327396 0.86 PTK2 (0.63) ALKINSRIGF1REGFRMET
SCHEMBL24327562 0.85 ALK (0.57) ALKINSRIGF1REGFRMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 — — US disclosed
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 — — US disclosed
WO-2022063106-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEIGENE, LTD. (KY) 2022-03-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS EGFR, ERBB2, ERBB4 ALK 13/4885INSR 82/4885IGF1R 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback